Viropharma Delayed as FDA Rejects Cold Treatment

CDW Computer warns; Gemstar slides on a net loss; plus more of today's stocks in the news

Viropharma (VPHM ) is delayed after an FDA advisory panel reportedly rejected the company's Picovir for the treatment of the common cold in adults.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.